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Background & Aims: Recent data suggest that poly-
morphisms in the organic cation transporter (OCTN)
genes OCTN1 (SLC22A4) and OCTN2 (SLC22A5) rep-
resent disease-causing mutations within the IBD5 lo-
cus (chromosome 5q31). We investigated associa-
tions with disease susceptibility, phenotype, and
evidence for epistasis with CARD15 in 679 patients
with Crohn’s disease (CD) or ulcerative colitis (UC).
Methods: A total of 374 patients with CD, 305 pa-
tients with UC, and 294 healthy controls (HCs) were
studied. Genotyping for single nucleotide polymor-
phisms IGR2096, IGR2198, and IGR2230, OCTN1
variant (SLC22A4 1672C¡T), and OCTN2 variant
(SLC22A5 207G¡C) was performed using the Taq-
Man system. Results: The IBD5 OCTN1 and OCTN2
polymorphisms were in strong linkage disequilibrium
(D=, >0.959). IGR2198 variant allele frequency
(49.1% vs 40.8%; P  .0046) and homozygosity (21%
vs 14.8%; P  .044) were associated with CD versus
HCs. Variant allelic frequency of OCTN1 (53.6% vs
43%; P  .0008) and OCTN2 (56.1% vs 48.4%; P 
.0092) polymorphisms and homozygosity for the
OCTN1/2-TC haplotype (28.4% vs 16%; P  .0042)
were associated with CD versus HCs. IGR2198 ho-
mozygosity and TC homozygosity were associated
with stricturing/penetrating disease at follow-up (P 
.011 and P  .011, respectively) and disease progres-
sion (P  .038 and P  .049, respectively) on univar-
iate analysis and with need for surgery on multivariate
analysis (P  .016 and P  .004, respectively). In the
absence of the IBD5 risk haplotype, no association of
OCTN1/2 variants with CD was detected. No associa-
tions were seen with UC. Conclusions: The IBD5 locus
inﬂuences susceptibility, progression, and need for
surgery in CD. However, the contribution of OCTN1/2
variants is not independent of the IBD5 haplotype; a
causative role for these genes remains plausible but
is not yet proven. Further genetic, functional, and
expression data are now required.
The inflammatory bowel diseases (IBDs), Crohn’s dis-ease (CD) and ulcerative colitis (UC), are common
causes of gastrointestinal morbidity in the Western
world. The incidence of early-onset disease continues to
increase in northern Europe, notably in Scotland and
Scandinavia.1–4 Epidemiologic, molecular, and clinical
studies have proven that genetic susceptibility combined
with environmental interaction are central to the patho-
genesis of IBD.5
Genome-wide scanning has identified susceptibility
loci for CD on chromosomes 1,6 5 (IBD5),7–9 6 (IBD3;
HLA),8,10 12 (IBD2),11 14 (IBD4),7,12 16 (IBD1),11,13
and 19 (IBD6).8 The most consistently replicated CD
susceptibility locus is located on chromosome 16 (IBD1),
and the susceptibility gene has been identified as the
NOD2/CARD15 gene.14,15 NOD2/CARD15 contains a
caspase recruitment domain (CARD) that is linked to a
nucleotide-binding domain and a leucine-rich repeat re-
gion. NOD2/CARD15 functions as an intracellular sen-
sor of muramyl dipeptide, a highly conserved pepti-
doglycan motif common to many intraluminal
bacteria.16,17 Watanabe et al suggested that NOD2/
CARD15/ mice lose negative control of Toll-like re-
ceptor 2–mediated activation of nuclear factor B, po-
tentially offering an explanation for the Th1 phenotype
characteristic of CD.18 However, recently published
studies do not provide support for NOD2/CARD15 in-
teraction with the Toll-like receptor 2 pathway, and
these data emphasize the complexity of NOD2/CARD15
activation.19,20
Two single nucleotide polymorphisms (SNPs)
(Gly908Arg and Arg702Trp) and a frameshift mutation
(Leu1007fsinsC) induce structural changes in the
leucine-rich region of NOD2/CARD15 and have been
associated with CD. Reported NOD2/CARD15 carriage
Abbreviations used in this paper: HC, healthy control; OCTN, organic
cation transporter; SNP, single nucleotide polymorphism.
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rates in CD vary between 0 and 50.0%, with highest
rates seen in central European populations,14,21 while
mutations are absent in Japanese and Chinese series.22,23
Lower frequencies have been reported from Finland and
Scotland, suggesting heterogeneity within Europe.24,25
NOD2/CARD15 polymorphisms have consistently been
associated with a younger age of onset of CD, ileal
disease, and fibrostenosing disease.26
The IBD5 locus on chromosome 5q31-33 was origi-
nally identified in 1999 as conferring susceptibility for
CD.7 This finding was replicated using linkage disequi-
librium mapping in the Canadian CD population and
further delineated to 5q31.8 Fine mapping of this area
has identified a single, highly conserved 250-kilobase
haplotype of 11 SNPs spanning a cytokine gene cluster
that is associated with CD.9 Further high-resolution
analysis of the 5q31 region using 103 SNPs revealed 11
discrete haplotype blocks that measure tens of kilobases
in length, have limited diversity, and are punctuated by
sites of recombination.27 Genotype-phenotype analysis
has suggested an association between the IBD5 locus,
perianal disease,28 and early onset of disease,29 but evi-
dence for epistasis between IBD5 and NOD2/CARD15
has been inconsistent.9,28–30
More recently, data have suggested that mutations of
2 genes within the IBD5 region, the organic cation
transporters OCTN1 (also known as SLC22A4) and
OCTN2 (SLC22A5), may be independently associated
with CD.31 The construction of a 2-allele risk haplotype
OCTN1/2-TC (SLC22A4 exon 9 1672C¡T and
SLC22A5 promoter 207G¡C) was reported to be
associated with CD in patients who lacked the extended
IBD5 risk haplotype. Individual allelic data were not
given.
OCTN1 is a 551–amino acid protein that is
strongly expressed in the kidney, trachea, bone mar-
row, and, to a lesser extent, small bowel and has been
characterized as a carnitine transporter.32 An intronic
SNP (rs2268277) in a Runt-related transcription fac-
tor 1 (RUNX1) binding site of OCTN1 has been
associated with susceptibility to rheumatoid arthritis
in the Japanese population.33 OCTN2 is a 557–amino
acid protein that is 75.8% homologous to OCTN1,
and functional studies have shown it to be a high-
affinity sodium carnitine transporter that is expressed
in the kidney, smooth muscle, and heart tissue.34
Peltekova et al suggested that the OCTN1 variant
(1672C¡T) alters its function in fibroblasts in vitro,
with variant forms having less affinity for carnitine
and a greater affinity for tetraethyl ammonium and
some xenobiotics, and that the OCTN2 variant
(207G¡C) disrupted a heat-shock transcription fac-
tor binding site in fibroblasts in vitro.31 No data
demonstrating the altered function or expression of
OCTN1/2 gene products in CD have yet been pro-
vided.
The provocative association data from Peltekova et al
have yet to be replicated in an independent population,
and epistasis with NOD2/CARD15 has not thus far been
assessed without the Canadian population. Phenotypic
data from the same Canadian cohort of patients with CD
have suggested a correlation between OCTN1/2 variants
and ileal disease, and this correlation becomes substan-
tially stronger when carriage of NOD/CARD15 variants
is taken into account.35 However, the phenotypic de-
scription of this cohort does not allow for analysis of
disease behavior, progression, or indeed proximal small
bowel disease.
In the present study, we assessed the contribution of
the OCTN1 and OCTN2 polymorphisms implicated by
Peltekova et al in determining genetic susceptibility in
CD and UC, specifically addressing whether these
OCTN1/2 variants have an association with susceptibil-
ity to IBD that is independent of other markers within
the extended IBD5 linkage interval. We also investi-
gated whether these polymorphisms are associated with
specific disease phenotype characteristics or progression
in our rigorously defined IBD population and assessed
gene-gene interactions with established NOD2/CARD15
mutations.
Materials and Methods
A total of 679 patients with well-characterized IBD
and 294 healthy controls (HCs) were recruited. All patients
with IBD attended the clinic at Western General Hospital
(Edinburgh, Scotland). This is a tertiary referral center for
IBD in southeastern Scotland. The IBD group comprised
374 patients with CD and 305 patients with UC. The
diagnosis of IBD adhered to the criteria of Lennard-Jones.36
Age at diagnosis, location, and behavior were classified
according to the Vienna classification.37 Phenotypic data
were collected by patient questionnaire, interview, and case
note review and were composed of demographics, date of
onset and diagnosis, disease location, disease behavior, pro-
gression, extraintestinal manifestations, surgical operations,
smoking history, joint symptoms, family history, and eth-
nicity. Written informed consent was obtained from all
patients. The Medicine and Oncology Subcommittee of the
Lothian Local Research Ethics Committee approved the
study protocol (LREC 2000/4/192).
Demographics
CD group. The demographics of the patients re-
cruited are shown in Table 1. The duration of follow-up was
defined as the time from diagnosis to the time of most
December 2005 OCTN1/2 VARIANTS WITHIN THE IBD5 LOCUS AND CD 1855
recent clinic review. Disease behavior at follow-up was
defined using the Vienna classification of behavior at the
time point when the disease was last clinically evaluated
(radiologically, endoscopically, or at surgery).24,37 In assess-
ing disease progression, patients who had Vienna B1 (in-
flammatory) CD at diagnosis were identified and disease
behavior was compared with behavior at most recent follow-
up. Patients were grouped as those who remained classified
as having inflammatory (B1) disease at follow-up (nonpro-
gressive disease), and those whose disease had progressed to
stricturing (B2) or penetrating (B3) disease. Ninety-seven
patients (26%) in the CD group were current smokers, and
79 (21%) had a first-degree relative with a family history of
IBD.
UC group. Clinical details were available regarding
the entire UC group. The group consisted of 171 men and 134
women with a median age at diagnosis of 34 years (Table 1).
Disease extent was recorded at diagnosis.
Control group. The control group comprised 294
healthy subjects: blood donors (n  163) recruited from
southeastern Scotland and healthy control subjects (n  131).
There were 143 men and 151 women with a median age of 39
years (interquartile range, 27–52 years).
Genotyping
Genomic DNA was extracted from peripheral venous
blood by a modified salting-out technique38 and resuspended
in 1 Tris-EDTA buffer (10 mmol/L Tris [pH 8.0] and 1
mmol/L EDTA [pH 8.0]) at a final concentration of 100
ng/L. To examine the relative contribution of the OCTN1/2
variants relative to the extended IBD5 haplotype, 3 SNPs were
genotyped: IGR2096 (which lies within haplotype block 4, as
defined by Daly et al27) (Figure 1), IGR2198 (within haplo-
type block 5), and IGR2230 (within haplotype block 7). The
rs1050152 polymorphism of the OCTN1 gene (SLC22A4
exon 9 1672C¡T, IGR3002) and the rs26313667 (SLC22A5
promoter 207G¡C, IGR2222) polymorphism of the
OCTN2 gene were typed. Details of these variants and of the
TaqMan primers are provided in Supplementary Table 1 (see
supplemental material online at www.mmc.med.ed.ac.uk/gi/
supdata.shtml) and Figure 1.
Patients with CD and HCs were typed for polymorphisms of
the NOD2/CARD15 gene (R702W, G908R, and 1007fsinsC)
using previously described methods.24 All genotyping except the
R702W polymorphism was performed using the TaqMan system
(7900HT sequence detection system; Applied Biosystems, Foster
Table 1. Demographics and Clinical Features of the CD, UC, and Control Groups
CD UC Controls
Total no. 374 305 294
Sex (male/female) 181/193 171/134 143/151
Median age at diagnosis, y (interquartile range) 27.8 (20.9–40.4) 34 (25–50) 39 (27–52)
Median duration of follow-up, y (interquartile
range)
11.8 (6.5–20.2) 7.5 (3.35–13.4)
non-Jewish White (%) 98.7 98.3
Age at diagnosis, A1 (younger than 40 years)/
A2 (older than 40)
72%/28%
Location at diagnosis (%)
Ileal disease (L1) 125 (34) Proctitis: 105 (34.5)
Colonic disease (L2) 139 (38) Left-sided colitis: 116 (37)
Ileal and colonic disease (L3) 58 (16) Extensive colitis:
84 (27.5)
Upper gastrointestinal disease (L4) 30 (8)
Oral CD 6 (2)
Perianal disease 75 (21)
Disease behavior at diagnosis (%)
Inflammatory (Vienna B1) 258 (74)
Stricturing (Vienna B2) 32 (9)
Penetrating (Vienna B3) 61 (17)
Disease behavior at follow-up (%)
Inflammatory (B1) 128 (34)
Stricturing (B2) 70 (19)
Penetrating (B3) 168 (48)
Disease progression
No progression from inflammatory (% of
inflammatory at diagnosis)
126 (49)
Inflammatory to structuring or penetrating (%) 132 (51)
Surgery for luminal complications of CD (%)a 237 (63)
NOTE. Disease behavior at follow-up was defined using the Vienna classification when the patient was last clinically evaluated. Full phenotypic
data were available on 94% of the patients with CD at diagnosis and 98% at follow-up. In assessing disease progression, patients were grouped
as those who remained as having inflammatory (B1), nonprogressive disease and those whose disease had progressed to stricturing (B2) or
penetrating (B3) disease.
aExamination under anesthesia or drainage procedures for perianal sepsis were excluded.
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City, CA). R702W genotyping was performed by restriction
fragment length polymorphism polymerase chain reaction. Re-
striction digestion was performed using 1 U Msp É at 37°C
overnight and polymerase chain reaction fragments run on 4%
NuSieve 3:1 agarose gels (Cambrex Bio Science, Nottingham,
Ltd, Nottingham, UK). These were stained with ethidium bro-
mide and viewed under UV light. An image was recorded
digitally.
Data Analysis
Each SNP was analyzed for association with IBD
overall, CD, UC, and disease phenotype. Allele frequencies
and carrier frequencies were determined for all polymor-
phisms. Each of the variants studied was shown to be in
Hardy–Weinberg equilibrium in patients and in controls.
Genotype-phenotype associations were analyzed by 2 test
using the Minitab statistical software package (Minitab Ltd,
Coventry, England). Linkage disequilibrium and haplotype
analysis were investigated using cocaphase (Rosland Frank-
lin Centre for genomics research; http://www.hgmp.mrc.a-
c.uk). Evidence for epistasis among the OCTN1/2 allelic
variants, the OCTN1/2-TC haplotype, and NOD2/CARD15
variants was investigated by comparing allelic frequencies
of the individual OCTN1/2 variants, together with ho-
mozygosity for the OCTN1/2-TC haplotype between the
subgroups of patients with and without NOD2/CARD15
variants by 2 analysis.
To identify significant independent variables associated
with genotype, multiple logistic regression analysis was
performed using the Minitab statistical software package
(Minitab Ltd). The population-attributable risk percentage
was defined as the excess rate of disease in individuals with
a mutation compared with those without. This was esti-
mated by the method of Schlesselman,39 which estimates
population-attributable risk percentage as equal to attrib-
utable risk as a function of the prevalence in the exposed
population divided by incidence of IBD in the population.
To calculate this, the prevalence of CD was estimated at
100/100,000 and the frequency of all alleles in the control
population was assumed to reflect that of the general pop-
ulation.
Results
Linkage Disequilibrium Across the IBD5
Locus
In the CD population, strong linkage disequilib-
rium was observed between the SNPs within the ex-
tended IBD5 haplotype as defined by Daly et al27:
IGR2096 (block 4), IGR2198 (block 5), OCTN2
(SLC22A5 promoter 207G¡C) (block 7), IGR2230
(block 7), and OCTN1 (SLC22A4 exon 9 1672C¡T)
(block 7) (Figure 1). Pairwise D= values0.959 between
each SNP confirmed the difficulty of showing an inde-
pendent effect of OCTN1/2 variants and IBD5. In the
detailed analyses of the IBD5 contribution to disease
phenotype presented in this report, data are presented for
the IGR2198 marker, representative of the 3-locus hap-
lotype (IGR2096, IGR2198, and IGR2230). All data are
available for each marker SNP on request.
Disease Susceptibility
Analysis of SNPs representing the extended IBD5
haplotype (IGR2096, IGR2198, and IGR2230). Variant
allelic frequencies differed significantly between patients
with CD and HCs for each of the 3 IBD5 SNPs studied
Figure 1. Haplotype structure and linkage disequilibrium across the IBD5 region. The IBD5 locus (5q31) with the high-resolution haplotype
structure as reported by Daly et al.27 (A) Candidate genes above the relevant haplotype blocks. Genes above the line are transcribed from left
to right, and those below the line are transcribed from right to left. (B) Eleven blocks numbered 1–11 (between 3 and 92 kilobases), each of
limited genetic diversity, are punctuated by sites of recombination. (C) D= scores are shown to demonstrate the tight linkage disequilibrium
between the SNPs that were analyzed. The lowest D= (0.959) was observed between IGR2096 and the OCTN2 variant (207G¡C). (D) Location
of the SNPs that were analyzed, with IGR2222 representing the OCTN2 variant (207G¡C) and IGR3002 representing the OCTN1 variant
(1672C¡T). IGR2078, which was used by Peltekova et al to represent the extended IBD5 haplotype, is located in block 4.31
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(IGR2096, 49.4% CD vs 41.9% HC [P  .03];
IGR2198, 49.1% CD vs 40.8% HC [P  .0046];
IGR2230, 54.9% CD vs 47.4% HC [P  .011]) (Table
2). Carriage rates for the IBD5 variants were significantly
higher in the patients with CD when compared with the
control population (IGR2096, 79.3% CD vs 68.7% HC
[P  .0034]; IGR2198, 77% CD vs 67% HC [P 
.011]; IGR2230, 80% CD vs 73.7% HC [P  .047]).
Individuals who were homozygous for the IBD5 risk
alleles at the 3 SNPs examined (IGR2096, IGR2198,
and IGR2230) were more common in the CD group than
in the control group (Table 2). The population-attribut-
able risk for IBD5 homozygosity was estimated as 15%
if IGR2096 data were considered in calculation, 14.0%
for IGR2198, and 14.3% for IGR2230.
No associations were observed between allelic fre-
quency of IBD5 variants and IBD overall (IGR2198,
45% IBD vs 40.8% HC [P  .077]) or UC (IGR2198,
43.7% UC vs 40.8% HC [P  .325]) (Supplementary
Table 2; see supplemental material online at www.mmc.
med.ed.ac.uk/gi/supdata.shtml).
Analysis of OCTN1/2 variants and OCTN1/2-TC
haplotype. Allelic frequencies differed between pa-
tients with CD and controls for the OCTN1 variant
(SLC22A4 exon 9 1672C¡T) (53.6% CD vs 42.9%
HC, P  .0008) and the OCTN2 variant (SLC22A5
promoter 207G¡C) (56.1% CD vs 48.4% HC, P 
.0092) (Table 2). Carriage of the OCTN1/2-TC risk
haplotype was present more frequently in patients
with CD than in controls (80% CD vs 68.5% HC, P
 .0016, OR, 1.8) (Table 2). It was clear that this
difference related to homozygosity because OCTN1/
2-TC homozygotes were more common in the CD
group (28.4% CD vs 16.1% HC, P  .0042, OR,
1.83). No significant difference was observed between
OCTN1/2-TC heterozygote rates (P  .3).
An association was observed between the OCTN1
variant and IBD when allelic frequencies were analyzed
(48.9% IBD vs 42.9% HC, P  .019). This finding was
not replicated in analysis of the OCTN2 variant (51.7%
IBD vs 48.4% HC, P  .162), and no associations were
observed between variant allelic frequencies of OCTN1
(44.7% UC vs 42.9% HC, P  .53) or OCTN2 (5% UC
vs 48.4% HC, P  .38) and UC (Supplementary Table
2; see supplemental material online at www.mmc.
med.ed.ac.uk/gi/supdata.shtml). No association was ob-
served between the OCTN1/2-TC haplotype and IBD
overall or with UC. There was no evidence of epistasis
Table 2. IBD5 Variant Allele Frequency, Carriage Rates, and Homozygote Frequency in Patients with CD and Controls
SNP/haplotype examined
Control frequency
(%)
CD frequency
(%) P
Odds ratio
(confidence
interval)
Variant allelic frequency
IGR2096 41.9 49.4 .03 1.42 (1.1–1.8)
IGR2198 40.8 49.1 .0046 1.40 (1.1–1.6)
OCTN2 (207 G¡C) 48.4 56.1 .0092 1.43 (1.2–1.8)
IGR2230 47.4 54.9 .011 1.35 (1.1–1.7)
OCTN1 (1672C¡T) 42.9 53.6 .0008 1.48 (1.2–1.9)
Variant carriage rates
IGR2096 173 (68.7) 264 (79) .0034 1.75 (1.2–2.6)
IGR2198 171 (67) 258 (77) .011 1.61 (1.2–2.3)
OCTN2 (207 G¡C) 187 (74) 280 (81) .034 1.52 (1.0–2.2)
IGR2230 185 (73.7) 261 (80) .047 1.5 (1.1–2.23)
OCTN1 (1672C¡T) 178 (68.7) 267 (80) .0024 1.77 (1.2–2.6)
TC haplotype 170 (69) 264 (80) .0016 1.8 (1.3–2.7)
IBD5 haplotypea 166 (63.6) 246 (73) .016 1.5 (1.1–2.2)
Variant homozygote frequency
IGR2096 38 (15.1) 73 (21.4) .036 1.58 (1.0–2.4)
IGR2198 38 (14.8) 70 (21) .044 1.56 (1.0–2.4)
OCTN2 (207 G¡C) 55 (22) 106 (31) .0155 1.59 (1.1–2.3)
IGR2230 47 (18.6) 94 (29) .0038 1.79 (1.2–2.6)
OCTN1 (1672C¡T) 44 (17) 89 (25.6) .011 1.69 (1.1–2.5)
TC haplotype 40 (16) 86 (28.4) .0042 1.83 (1.2–2.8)
IBD5 haplotypea 38 (14.6) 68 (20.5) .071 1.48 (1.0–2.3)
NOTE. Three SNPs were used to define the extended IBD5 locus (IGR2096, IGR2198, and IGR2230) (Figure 1). Each was independently
associated with susceptibility to CD when allelic frequencies, carriage rates, and homozygosity were analyzed. OCTN2 variant (207G¡C) and
OCTN1 variant (1672C¡T) were also independently associated with susceptibility to CD when allelic frequencies, carriage rates, and
homozygosity were analyzed. The 2-allele risk haplotype OCTN1/2-TC haplotype was associated with susceptibility to CD when carriage rates and
homozygosity rates were analyzed.
aA 2-allele risk haplotype using the IBD5 marker SNPs IGR2198 and IGR2230 is also illustrated for comparison with the OCTN1/2-TC haplotype.
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between the OCTN1/2 variants, the OCTN1/2-TC hap-
lotype, and CARD15 variants (Table 3).
The OCTN1/2 association with CD is not indepen-
dent of the association with the extended IBD5 haplo-
type. Previous data have suggested carriage of the OCTN1/
2-TC haplotype to be an independent risk factor for CD.
However, in our data set, for individuals who lacked the
IBD5 risk haplotype (homozygous with respect to the non–
CD-associated alleles of IGR2096, IGR2198, and
IGR2230), the OCTN1/2-TC haplotype was not associated
with CD (Table 4). In the absence of variants in the marker
SNP IGR2096, which is located in block 427 (Figure 1),
21.5% of the controls carried the OCTN1/2-TC haplotype
compared with 30.4% in the CD group (P  .22). When
the OCTN1/2-TC haplotype was analyzed in the absence of
IGR2198 variants (block 5), 27.1% of the controls pos-
sessed the OCTN1/2-TC haplotype versus 17.1% of the
patients with CD (P .13). In the absence of variants in the
marker SNP IGR2230, which is in the same block as
OCTN1/2 (block 7), 3% of the controls possessed the
OCTN1/2-TC haplotype versus 1.6% of the patients with
CD (P  .59).
Phenotypic Analysis
Age at diagnosis. No association was observed
between the age at diagnosis in patients with IBD
overall, or UC and the IBD5 OCTN1/2 variant alleles.
When allelic frequency was compared in subgroups
defined by the Vienna classification for age in the pa-
tients with CD (A1, younger than 40 years; A2, older
than 40 years), there was no significant difference be-
tween variant and wild-type allelic frequency for all
studied SNPs.
Anatomic distribution. There was no association
between the IBD5marker SNPs, OCTN1/2 variants, and
CD when disease location was assessed by the Vienna
classification (L1, terminal ileum; L2, colon; L3, ileoco-
lonic; L4, upper gastrointestinal tract). Of note, no as-
sociation was found between the presence of perianal CD
Table 3. Frequency of OCTN1/2 Variant Alleles and the OCTN1/2-TC Haplotype in Patients with CD Stratified by Carriage of
NOD2/CARD15 Variants
SNP/haplotype examined
% NOD2/CARD15-positive
patients
(n  84)
% NOD2/CARD15-negative
patients
(n  188) P
OCTN2 (207 G¡C) allelic frequency 55.2 56.3 .78
OCTN1 (1672C¡T) allelic frequency 51.9 53.4 .69
OCTN1/2 TC haplotype carriage 72.3 71.1 .79
OCTN1/2 TC haplotype homozygosity 22.0 24.5 .574
NOTE. Analysis of evidence for epistasis between OCTN2 variant (207G¡C) and OCTN1 variant (1672C¡T) and the TC haplotype of OCTN1/2
was investigated by stratifying OCTN1/2 variants by carriage of one or more of the 3 common CARD15 variants: R702W, G908R, and
1007fsinsC. No evidence of epistasis was observed.
Table 4. Frequency of the OCTN1/2 TC Haplotype in Individuals Not Possessing Disease Susceptibility Risk Alleles at the
Markers IGR2096, IGR2198, and IGR2230
No. of subjects
not possessing
IGR2096
variants
OCTN1/2-TC
haplotype
frequency
(%)
No. of subjects
not possessing
IGR2198
variants
OCTN1/2-TC
haplotype
frequency
(%)
No. of subjects
not possessing
IGR2230
variants
OCTN1/2-TC
haplotype
frequency
(%)
No. of subjects
not possessing
IGR2096,
IGR2198, and
IGR2230
variants
OCTN1/2-TC
haplotype
frequency
(%)
Controls 79 17 (21.5) 85 23 (27.1) 66 2 (3) 63 2 (3.2)
Patients
with CD
69 21 (30.4) 76 13 (17.1) 62 1 (1.6) 41 0
P .22 .13 .59 .25
NOTE. The number of patients with CD and controls are shown in the absence of the IBD5 risk haplotype markers IGR2096, IGR2198, and
IGR2230 and all 3 SNPs combined. The location of these marker SNPs within the IBD5 locus is illustrated in Figure 1. The frequency of the
OCTN1/2-TC haplotype within each of these respective groups is illustrated together with P values. In these individuals not possessing allelic
variants associated with the extended IBD5 haplotype, the OCTN1/2-TC haplotype was not significantly associated with CD for any of the 3
markers, providing evidence against an independent effect of the OCTN1/2 haplotype on disease susceptibility. In the data set from Peltekova
et al, the single marker IGR2078 (block 4) was used to define the IBD5 risk haplotype. It is noteworthy that IGR2096, the only marker of the 3
studied in our population to show even a trend toward independent segregation from OCTN1/2, was the marker farthest from OCTN1/2 and also
was closest to the single marker used by Peltekova et al.
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and homozygosity for the OCTN1/2-TC haplotype (P 
.875). When patients with CD were further stratified for
NOD2/CARD15 variant carriage, no associations be-
tween homozygosity for the OCTN1/2-TC haplotype
and the disease location, categorized by the Vienna clas-
sification, were observed; 45% of OCTN1/2-TC homozy-
gous patients with CD with terminal ileal disease (L1)
carried no NOD2/CARD15 variants, whereas 52% car-
ried 1 or more NOD2/CARD15 variants (P  .75). The
IBD5 OCTN1/2 variants were not associated with dis-
ease extent and severity in the UC cohort.
Disease behavior. When disease behavior at di-
agnosis was analyzed, no significant association between
variants representing the extended IBD5 locus, individ-
ual OCTN1/2 variants, and stricturing (B2, Vienna clas-
sification) or penetrating (B3) behavior was observed
when compared with inflammatory, nonstricturing, non-
penetrating disease behavior (B1). A significant associa-
tion was observed between IGR2198 homozygosity and
stricturing/penetrating disease when compared with in-
flammatory disease at most recent follow-up (24.9% B2
and B3 vs 14.4% B1; P  .026; OR, 1.97) (Table 5).
Significant associations were also observed between stric-
turing/penetrating disease when compared with inflam-
matory disease for OCTN1 variant homozygosity (30%
B2 and B3 vs 17.4% B1; P  .011; OR, 2.0), OCTN2
variant homozygosity (34.8% B2 and B3 vs 23.0% B1;
P .029; OR, 1.78), and homozygosity for the OCTN1/
2-TC haplotype (29.7% B2 and B3 vs 17.1% B1; P 
.011; OR, 2.05). In individuals who lacked the IBD5
risk haplotype (homozygous with respect to the non–
CD-associated allele of the IGR2198 variant), there was
no association between stricturing/penetrating disease
behavior at follow-up and homozygosity for the OCTN1/
2-TC haplotype (11.1% inflammatory vs 14.9% strictur-
ing/penetrating; P  .65).
Disease progression. Because the Vienna classi-
fication is a hierarchical system, a number of patients will
move from inflammatory disease (B1) at diagnosis to
either stricturing (B2) or penetrating (B3) disease during
their follow-up. Of the 258 patients who had inflamma-
tory disease at diagnosis, 126 patients remained in the
inflammatory group at follow-up and 132 patients pro-
gressed to the stricturing group or the penetrating
group. The median duration of follow-up of these pa-
tients was 11.8 years. Homozygosity rates of IGR2198
variants and the OCTN1/2-TC haplotype were associated
with disease progression to B2 or B3 compared with
those whose disease remained as B1 (Table 5). The
association between the OCTN1/2-TC haplotype and
disease progression was not observed in patients with CD
who lacked the IBD5 risk haplotype (18% progression vs
13% nonprogression; P  .56).
Requirement for surgery. As a marker of disease
severity, patients who had required surgery (n 237) for
complications of luminal CD were compared with those
who had had no surgery for CD (n  137). A significant
association was observed between requirement for sur-
gery and homozygosity for variants of IGR2198,
Table 5. Phenotypic Associations of IGR2198, OCTN1/2 Variant Homozygosity, and Homozygosity for the OCTN1/2-TC
Haplotype
Phenotype
Patients with CD homozygous for the variant allele/haplotype
IGR2198
OCTN2
(207 G¡C)
OCTN1
(1672C¡T)
OCTN1/2 TC
haplotype
Vienna classification of disease
behavior at follow-up
Inflammatory (n  121) 14.4% 23.0% 17.4% 17.1%
Stricturing/penetrating (n  217) 24.9% 34.8% 30.0% 29.7%
P (relative risk) .026 (1.97) .029 (1.78) .011 (2.0) .011 (2.05)
Disease progression from diagnosis to
follow-up
No progression (n  126) 14.7% 23.4% 18.2% 17.8%
Progression (n  132) 25.9% 31.3% 26.9% 29.1%
P (relative risk) .038 (1.72) .18 (1.49) .12 (1.66) .049 (1.63)
Surgery for luminal complications of CD
No surgery (n  137) 13.1% 21.9% 11.7% 12.3%
Surgery (n  237) 23.2% 33.1% 26.6% 26.7%
P (odds ratio) .037 (1.91) .031 (1.77) .0007 (2.7) .0023 (2.2)
NOTE. An association was observed between IGR2198 variant homozygosity, OCTN2 variant homozygosity, OCTN1 variant homozygosity, and
homozygosity for the OCTN1/2-TC haplotype and structuring/penetrating disease when compared with inflammatory disease at most recent
follow-up. Of the 258 patients with CD who had inflammatory Vienna disease classification at diagnosis, 126 patients did not progress at
follow-up and 132 patients progressed to the stricturing/penetrating group. The average duration of follow-up of these patients was 11.8 years.
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OCTN1, OCTN2, and the OCTN1/2-TC haplotype (Ta-
ble 5).
Multiple logistic regression analysis was applied, us-
ing a model that considered age at diagnosis, disease
behavior, smoking status, family history, NOD2/
CARD15 carrier status, and IGR2198 homozygosity or
the OCTN1/2-TC haplotype, with the outcome being
surgery for luminal complications of CD. Colinearity
between IGR2198 and OCTN1/2-TC homozygosity was
evident and allowed for in modeling. IGR2198 homozy-
gosity (P  .016; odds ratio, 2.86; confidence interval,
1.21–6.76) and the OCTN1/2-TC haplotype (P  .004;
odds ratio, 3.52; confidence interval, 1.49–8.31) were
significantly associated with the need for surgery.
Discussion
The present study has provided novel data regard-
ing the contribution of the IBD5 locus as a determinant
of disease susceptibility and phenotype in the Scottish
population, which is known to be characterized by low
rates of racial admixture compared with others in Europe
and North America.40 We have shown the OCTN1 and
OCTN2 polymorphisms to be in tight linkage disequi-
librium (D=,0.959), with allelic variants of the 3 SNPs
representing the extended IBD5 haplotype (IGR2096,
IGR2198, and IGR2230). Susceptibility to CD was as-
sociated with each of the 3 IBD5 polymorphisms defin-
ing the extended IBD5 region and the variant alleles of
the OCTN1 and OCTN2 genes. Homozygosity for each
of the 3 SNPs used to define the extended IBD5 haplo-
type and for the OCTN1/2-TC haplotype was strongly
associated with disease susceptibility. These data provide
the first independent confirmation of the association with
the OCTN1/2 variants studied by Peltekova et al in
Canada.31
However, our data are not entirely consistent with the
results reported by Peltekova et al in a potentially critical
aspect. In the absence of allelic variants representing the
extended risk haplotype for IBD5, our results showed no
significant difference in the presence of the OCTN1/
2-TC haplotype in patients with CD compared with
controls. These findings lead to the important suggestion
that the OCTN1/2-TC haplotype may not confer risk of
CD independently of other closely linked determinants
within the extended IBD5 locus and that it is at present
premature to conclude that the OCTN1/2 variants are
causative in the pathogenesis of CD.
In comparing the studies reported by Peltekova et al
with our own, the choice of markers used to define the
IBD5 locus is especially worthy of discussion. In the data
set from Peltekova et al, the single marker IGR2078,
located in block 4 of the haplotype map27 (Figure 1), was
used to define the IBD5 risk haplotype and not a marker
closer to the OCTN1/2 loci (block 7), such as IGR2198
(block 5) or IGR2230 (block 7), which were used in the
present study. In light of this, recombination between
the IGR2078 marker in block 4 and OCTN1/2 in block
7 needs to be considered as an explanation for the ap-
parent independence reported by Peltekova et al. In our
data, the only marker for which any trend toward an
independence of the OCTN1/2-TC haplotype was ob-
served concerned the IGR2096 variants, which are also
located in block 4. In the absence of variants of the
markers IGR2198 and IGR2230, the OCTN1/2-TC
haplotype was in fact more prevalent in the control
group, further supporting the hypothesis of recombina-
tion between haplotype blocks 4 and 7.27
Recent data presented in abstract form involving 3
large cohorts of patients with IBD (more than 1200
patients with CD in total) in Cambridge,41 Stockholm,
Sweden (Törkvist et al, personal communication, May
2005), and the United Kingdom/Germany42 have all
shown an association between the IBD5 locus and CD. In
each of these data sets, as in the present study, there was
no independent association between the OCTN1/2-TC
haplotype and CD in the absence of the extended IBD5
risk haplotype.
The arguments as to the contribution of the OCTN1/2
variants implicated by Peltekova et al have been devel-
oped further recently and clearly require resolution.
Studies involving 276 samples from healthy, ethnically
diverse human populations have allowed the identifica-
tion of several nonconservative SNPs of OCTN1/2 in
evolutionary conserved sites in black and Chinese popu-
lations.43 The investigators suggest that if these variants
were shown to confer susceptibility to CD in their re-
spective populations, this would provide strong evidence
that OCTN1/2 contain the critical mutations. As yet,
these studies have not been undertaken. Moreover, ge-
netic mutations in OCTN2 cause systemic carnitine
deficiency, characterized by disease of skeletal muscle,
cardiac muscle, and liver but not inflammatory or intes-
tinal disease.44
Genetic studies to resolve the limits of the association
using markers p and q telomeric to OCTN1/2 may help
to clarify this issue; however, power of resolution will
become a critical issue in attempting to resolve this
controversy by genetic studies alone. We have calculated
that 3200 individuals with CD would need to be geno-
typed to prove the independence of OCTN1/2 from
IGR2230, which is situated between the 2 genes in
haplotype block 7.27 Complementary approaches such as
functional and expression studies in CD are clearly re-
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quired. Whereas OCTN1/2 remain strong and plausible
candidates within the haplotype structure on 5q31, the
case is yet to be proven beyond doubt.
Other immunoregulatory genes that have the poten-
tial to play a role in the pathogenesis of CD and are
located on the IBD5 haplotype are interleukin-3, inter-
leukin-4, interleukin-5, and CSF2.9 The interleukins
have a well-defined role in immune regulation, and CSF2
encodes for granulocyte-macrophage colony–stimulating
factor.9,45
Increasingly, in CD, it is recognized that clinical
phenotype is genetically determined.46 In our cohort,
when the Vienna classification for disease behavior was
analyzed at the patients’ most recent follow-up assess-
ment, there was a significant association between the
IBD5 marker SNP IGR2198, OCTN1/2 variants, the
OCTN1/2-TC haplotype, and the presence of stricturing
and penetrating disease. Patients with CD who were
homozygous for IGR2198 variants or homozygous for
the OCTN1/2-TC haplotype had a disease phenotype
that was more likely to progress to stricturing or pene-
trating disease behavior, and multivariate analysis
showed an association among IGR2198, the OCTN1/
2-TC haplotype, and the requirement for surgery, a
surrogate marker for severity in CD.47
It is important to point out that all the genotype-
phenotype data contained within our study are internally
consistent, with the significant association of the IBD5
OCTN1/2 variants, stricturing and penetrating disease
at latest follow-up, and disease progression from inflam-
matory to stricturing and penetrating disease, because
these patients with progressive complicated disease are
more likely to require surgical intervention. Although no
classification system has gained universal approval, the
Vienna classification is increasingly widely used and is
currently subject to reevaluation.48 Variants within the
IBD5 locus have also been associated with a more severe
disease phenotype and growth failure in an independent
cohort of 200 Scottish patients diagnosed with CD at 16
years of age or younger.49 Overall, our data show an
exciting, novel genotype-phenotype association with the
IBD5 locus, and it is intriguing to propose that a genetic
variant within the IBD5 locus causes CD to become more
severe (stricturing or penetrating disease) and hence re-
quire increased surgical intervention.
Previous work involving the IBD5 locus has shown an
association between the IBD5 risk haplotype and peri-
anal CD, but this was not replicated in our cohort.28
Phenotypic data from Newman et al showed an associa-
tion with ileal disease,35 but no significant association
was observed in our population; 32.2% of patients with
ileal CD were OCTN1/2-TC homozygous and 78% car-
ried the OCTN1/2-TC haplotype compared with 22.6%
of patients with nonileal CD who were OCTN1/2 ho-
mozygotes and 75.5% of whom carried the OCTN1/
2-TC haplotype (P  .075 and P  .63, respectively).
Differences in definitions of ileal CD may be the reason
for the differences between these 2 cohorts; ileal disease
in our cohort was classified strictly according to the
Vienna classification (L1). Using these criteria, 34% of
patients had purely terminal ileal disease; in contrast,
70.6% of patients in the Toronto cohort were classified as
having ileal disease.35 Newman et al did not appear to
include any patients with proximal small intestinal or
upper gastrointestinal disease. No data were available in
this cohort regarding disease behavior or disease progres-
sion over time.
NOD2/CARD15 variants have consistently been asso-
ciated with a younger age of onset of disease, ileal disease,
and stricturing disease.26 In the present study, no evi-
dence of epistasis was observed between the OCTN1/2
variants and NOD2/CARD15 variants. Genetic hetero-
geneity between the Scottish population and that of
Canada may be responsible for observed differences in
this context, and it is pertinent to note the low frequency
of CARD15 variants in the Scottish CD population
(1007fsinsC, 4.7%; G908R, 1.8%; R702W, 7.1%) and
the low combined population-attributable risk these
variants confer, which is estimated at 11%.24
In conclusion, we have determined that the IBD5
locus is associated with disease susceptibility in our CD
cohort in Scotland. This is the first independent replica-
tion of the association of the OCTN1/2 haplotype with
CD outside the index population in Canada. However, a
significant effect of OCTN1 and OCTN2 variants was
not seen in the absence of the IBD5 risk haplotype, and
on the strength of the present data it is not possible to
conclude whether or not the OCTN1/2 genes contain the
disease-causing mutation or whether the association
serves to only narrow the region of association within the
IBD5 locus. Finally, novel and potentially important
phenotypic associations have been identified with the
IBD5 locus, which implicate this region as a determinant
of disease severity in CD as well as susceptibility.
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